Life Technologies Corp Enters Into License and Supply Agreement With Novartis AG For Dynabeads

Wednesday, 31 Jul 2013 08:01am EDT 

Life Technologies Corporation announced that the Company has signed a long-term supply and exclusive licensing agreement with Novartis AG for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer. Life Technologies will provide the Company's proprietary technology, Dynabeads CD3/CD28 CTS, which possess biological properties suited to production of active, therapeutically relevant immune system cells. The agreement includes rights to use Life Technologies' intellectual property to perform the resulting therapy, and is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer. 

Company Quote

0.35 +0.41%
11:31am EDT